Dr. Yaron Daniely is the CEO and President of Yissum, the Technology Transfer company of The Hebrew University of Jerusalem. Before joining Yissum in 2017, he served for eight years as President, CEO and Director of Alcobra Ltd. Prior to his appointment at Alcobra, Yaron was
President and CEO of NanoCyte, Inc (2004-2007), based in Caesarea, Israel, where he focused on developing transdermal delivery technologies.
Previously, Yaron held a number of leadership positions, including General Manager and VP of Business Development at Gamida Cell-Teva Joint Venture, Ltd, a joint venture company based in Jerusalem, Israel which acquired an exclusive license to develop and commercialise a Phase
3-stage cell therapy product for treatment of Leukemia and Lymphoma. Additionally, he co-founded and served as Director of Bioblast Ltd. (NASADQ:ORPN).
Yaron earned a B.Sc. in Biological Sciences from Florida International University, and a PhD from the Sackler Institute of Graduate Biomedical Sciences at the NYU School of Medicine. Following his doctoral porgramme, Yaron served as an NIH Visiting Fellow in its Cell Biology section
and as a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. Subsequently, he received an Executive MBA from the Technion-Israel Institute of Technology.
Yaron co-founded Israel’s first M.B.A. porgramme specialising in Biomedical Management at the College of Management Academic Studies (Rishon LeZion, Israel) and has served as the programme’s director since its inception.